Forbion
Portfolio in Switzerland · United Kingdom · Norway: 5 funded startups tracked by Uback, 5 of them in a ranking.
Portfolio on Uback
Sorted by Uback rank, then Radar by last round| Company | Uback | Sector | Round backed | Valuation (AI) |
|---|---|---|---|---|
| Calluna Pharma | #3 Norway | Biotech › immunology antibodies | Series A · USD 82M · Jan 2024 | Hundreds of M$ |
| Noema Pharma | #13 Switzerland | Biotech › CNS drugs | Series B (incl. extension) · USD 150M · Dec 2024 | Hundreds of M$ |
| Granite Bio | #20 Switzerland | Biotech › immunology antibodies | Series A + B · USD 100M · Apr 2025 | Hundreds of M$ |
| Mosanna Therapeutics | #24 Switzerland | Biotech › sleep apnea | Series A · USD 80M · Jun 2025 | Hundreds of M$ |
| Solasta Bio | #19 Biological inputs | Food & agriculture › Agriculture › Biological inputs | Series A · USD 14M · Sep 2024 | Tens of M$ |
Only startups that meet Uback’s eligibility rules are shown. Amounts are round sizes, not the fund’s share. Rounds as reported by public sources.
By sector
Deals tracked per year
Co-investors
EQT Life Sciences ×2 · Jeito Capital · Versant Ventures · Novartis Venture Fund · Sanofi Ventures · Pivotal bioVenture Partners · Broadview · Norwest Venture Partners · Sarsia · p53 · Investinor · FMC Ventures · Corteva Catalyst · Cavallo Ventures · Scottish Enterprise
Investors that joined the same rounds, as reported by public sources.
Last updated: Oct 2026Report a missing dealReport an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction.